Ventyx Biosciences (NASDAQ:VTYX – Get Free Report)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports.

In his iconic song The Gambler, Kenny Rogers famously sang, “Every hand’s a winner, and every hand’s a loser.” This line offers valuable ...

Ventyx Biosciences, Inc. ( (VTYX) ) has released its Q3 earnings. Here is a breakdown of the information Ventyx Biosciences, Inc. presented to its investors. Ventyx Biosciences, Inc. is a clinical ...

Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials ...

EST Ventyx Biosciences (VTYX) files to sell 7.06M shares of common stock for holders Published first on TheFly – the ultimate ...

A webcast of the presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after ...

Sanofi will keep a significant stake in the ... in their technology within immunology and neurology. We've invested in Ventyx, focused in autoimmune and inflammatory disorders with an NLRP3 ...

Cash, cash equivalents and marketable securities were $274.8 million as of September 30, 2024. “We believe our current cash, cash equivalents and marketable securities are sufficient to fund our ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...